Viatris (VTRS) Research & Development (2020 - 2026)
Viatris' (VTRS) quarterly Research & Development came in at $248.6 million in Q1 2026, up 11.98% year-on-year from $222.0 million in Q1 2025, and up 138.67% quarter-over-quarter from -$642.9 million in Q4 2025.
Viatris (VTRS) Research & Development (2020 - 2026) Analysis & Trends
Viatris' Research & Development history runs 7 years deep, the most recent figure standing at $248.6 million for Q1 2026.
- On a quarterly basis, Research & Development rose 11.98% year-over-year to $248.6 million in Q1 2026; TTM through Mar 2026 was $74.9 million, a 48.02% increase from a year earlier, with the FY2025 full-year figure at $48.3 million, up 70.67% from the prior year.
- Research & Development rose to $248.6 million in Q1 2026 per VTRS's latest filing, from -$642.9 million in the prior quarter.
- Across five years, Research & Development topped out at $662.2 million in Q4 2022 and bottomed at -$642.9 million in Q4 2025.
- The 5-year median for Research & Development is $199.0 million (2024), against an average of $111.4 million.
- Biggest YoY gain for Research & Development was 1900.98% in 2024; the steepest drop was 708.59% in 2024.
- Year by year, Research & Development stood at $662.2 million in 2022, then sank by 85.76% to $94.3 million in 2023, then plunged by 708.59% to -$573.9 million in 2024, then fell by 12.02% to -$642.9 million in 2025, then jumped by 138.67% to $248.6 million in 2026.
- Per Business Quant, the three latest VTRS Research & Development figures stand at $248.6 million (Q1 2026), -$642.9 million (Q4 2025), and $250.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 696.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 180.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 7.37 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 138.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 248.60 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 296.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 97.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 248.60 Mn |
| Dec 31, 2025 | -642.90 Mn |
| Sep 30, 2025 | 250.40 Mn |
| Jun 30, 2025 | 218.80 Mn |
| Mar 31, 2025 | 222.00 Mn |
| Dec 31, 2024 | -573.90 Mn |
| Sep 30, 2024 | 198.40 Mn |
| Jun 30, 2024 | 204.10 Mn |
| Mar 31, 2024 | 199.70 Mn |
| Dec 31, 2023 | 94.30 Mn |
| Sep 30, 2023 | 211.20 Mn |
| Jun 30, 2023 | 10.20 Mn |
| Dec 31, 2022 | 662.20 Mn |
| Sep 30, 2022 | 174.90 Mn |
| Jun 30, 2022 | 162.60 Mn |
| Mar 31, 2022 | 142.30 Mn |
| Dec 31, 2021 | -413.80 Mn |
| Sep 30, 2021 | 152.10 Mn |
| Jun 30, 2021 | 147.70 Mn |
| Mar 31, 2021 | 184.10 Mn |